Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cocaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lannett Receives Fda Approval To Manufacture Numbrino® At Seymour Plant
Details : Numbrino™ (Cocaine Hydrochloride Nasal Solution) company's branded topical anesthetic product for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults.
Brand Name : Numbrino
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 21, 2022
Lead Product(s) : Cocaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : HEC Group
Deal Size : Not Applicable
Deal Type : Not Applicable
Lannett Announces Subject Dosing Complete For Pivotal Clinical Trial Of Biosimilar Insulin Glargine
Details : Biosimilar insulin glargine is the most significant opportunity in the company's current pipeline. Recent estimated U.S. sales of long acting insulin glargine (Glaricon) are approximately $10 billion annually, according to IQVIA, although manufacturer re...
Brand Name : Glaricon
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 31, 2022
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : HEC Group
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Verapamil Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : Societal CDMO
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under terms of the amendment, Societal will now receive improved overall economics, including a 10% increase in the profit share component of revenue from Verapamil PM product sales, as well as immediate and scheduled increases in manufacturing prices.
Brand Name : Verelan PM
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 12, 2022
Lead Product(s) : Verapamil Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : Societal CDMO
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lannett Initiates Pivotal Clinical Trial for Biosimilar Insulin Glargine
Details : The first study, which the FDA reviewed, suggested that the HEC insulin glargine product would be biosimilar to US-approved Lantus® (the reference biologic) in terms of meeting the study's pharmacokinetics (PK) and pharmacodynamics (PD) endpoints.
Brand Name : HEC-Glargine
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 29, 2022
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Recipient : Respirent Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
LANNETT Expands Respiratory Pipeline, Signs Exclusive Commercialization
Details : Lannett Company has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva® Handihaler® (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals Co. Ltd.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 29, 2021
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Recipient : Respirent Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lannett Submits ANDA For Generic ADVAIR DISKUS®
Details : Respirent Pharmaceuticals has summited an Abbreviated New Drug Application for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the U.S. FDA. The product is the generic equivalent of ADVAIR DISKUS of Glax...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 01, 2021
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Respirent Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Lannett announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Flovent® Diskus® (Fluticasone Propionate Powder Inhaler) of Respirent Pharmaceuticals.
Brand Name : Flovent Diskus
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 17, 2020
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Respirent Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Mexiletine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : RIVOPHARM SA
Deal Size : Undisclosed
Deal Type : Collaboration
Lannett Launches Mexiletine HCl Capsules
Details : Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a percentage of net profits. Other financial terms were not disclosed.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 23, 2020
Lead Product(s) : Mexiletine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : RIVOPHARM SA
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Levothyroxine Sodium
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Cediprof
Deal Size : Undisclosed
Deal Type : Agreement
Lannett and Cediprof Announce Exclusive Distribution Agreement for An Approved Levothyroxine
Details : The companies have entered into an interim exclusive supply and distribution agreement for Cediprof's FDA approved Levothyroxine Sodium Tablets USP. Lannett to Commence Marketing on August 3, 2020.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 16, 2020
Lead Product(s) : Levothyroxine Sodium
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Cediprof
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : At the Biosimilar Biological Product Development Type II meeting the FDA provided positive feedback on the clinical and Chemistry, Manufacturing and Controls advancement of company's biosimilar insulin glargine that was consistent with our expectations.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 11, 2020
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?